Yet, the hemostatic medication Factor VII’s capacity to diminish HE was most potent during the first 2.5 h, as demonstrated in the Factor VII for Acute Hemorrhagic Stroke Trial (FAST) experiment (97, 98). The gene discussed is F7; the disease is hereditary elliptocytosis.